Waters Debuts Industry-First Extended-Range MALS Detector for UHPLC/UPLC, Powering Rapid Characterization of Large Molecules
Delivers up to 4x faster chromatographic run times to accelerate decisions across…
Unison Supports Large Federal Agency Program with Bulk Contract Modifications to Comply with New RFO Guidance
MCLEAN, Va., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Unison, the leading provider…
Hettich India recognised among the Top 50 India’s Best Workplaces in Manufacturing 2026 – Large Category
MUMBAI, India, Feb. 2, 2026 /PRNewswire/ -- Hettich India has been recognised…
BIO-key and Visualforma Awarded Contract to Secure Digital Identities for Large Municipality in Portugal
HOLMDEL, N.J. and FARO, Portugal, Jan. 28, 2026 (GLOBE NEWSWIRE) -- BIO-key…
Strong Q3 Performance: Sequential Revenue Growth of 0.6% in CC, Large Deal Wins of $4.8 billion
Revenue Guidance for FY 26 revised to 3.0%-3.5%BENGALURU, India, Jan. 14, 2026…
Online Casino Real Money No Deposit Bonus Get $5 No Deposit Bonus + Large Welcome Bonus By BC Poker
New York City, NY, Dec. 27, 2025 (GLOBE NEWSWIRE) -- Players searching…
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
93% overall response and 76% complete response rates with median progression-free survival…
Windtree Therapeutics Announces Large Reduction of Preferred Series C and D Shares Outstanding by Conversion and Redemption
July 29, 2025 09:01 ET | Source: Windtree Therapeutics Investors choose to…
Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)
Media ReleaseCOPENHAGEN, Denmark; June 15, 2025 Results from the EPCORE® NHL-2 trial…
